<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hong W</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>NICHD NIH HHS</funding><funding>Philanthropic donation</funding><funding>NINDS NIH HHS</funding><pagination>591-604</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9876658</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>36(6)</volume><pubmed_abstract>Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a developmental and epileptic encephalopathy with infantile-onset epilepsy. Most individuals with CDD develop refractory epilepsy with multiple seizure types. Management of seizures in CDD remains challenging for clinicians given the highly refractory nature of seizures and the limited number of disease-specific studies that offer a high level of evidence. Epileptic spasms are the most common seizure type in CDD and are more often refractory to standard first-line treatment than are spasms of other etiologies. In other seizure types, the effectiveness of antiseizure medications is limited and wanes over time. Ketogenic diet and palliative surgical treatments have both had mixed results in observational studies. When treati</pubmed_abstract><journal>CNS drugs</journal><pubmed_title>CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment.</pubmed_title><pmcid>PMC9876658</pmcid><funding_grant_id>K23 NS107646-04</funding_grant_id><funding_grant_id>K23 NS107646</funding_grant_id><funding_grant_id>U01 NS114312</funding_grant_id><funding_grant_id>P50 HD105351</funding_grant_id><pubmed_authors>Demarest S</pubmed_authors><pubmed_authors>Olson HE</pubmed_authors><pubmed_authors>Weisenberg JL</pubmed_authors><pubmed_authors>Haviland I</pubmed_authors><pubmed_authors>Pestana-Knight E</pubmed_authors><pubmed_authors>Hong W</pubmed_authors><pubmed_authors>Marsh ED</pubmed_authors></additional><is_claimable>false</is_claimable><name>CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment.</name><description>Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a developmental and epileptic encephalopathy with infantile-onset epilepsy. Most individuals with CDD develop refractory epilepsy with multiple seizure types. Management of seizures in CDD remains challenging for clinicians given the highly refractory nature of seizures and the limited number of disease-specific studies that offer a high level of evidence. Epileptic spasms are the most common seizure type in CDD and are more often refractory to standard first-line treatment than are spasms of other etiologies. In other seizure types, the effectiveness of antiseizure medications is limited and wanes over time. Ketogenic diet and palliative surgical treatments have both had mixed results in observational studies. When treati</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-22T04:50:38.255Z</modification><creation>2025-04-05T21:08:40.342Z</creation></dates><accession>S-EPMC9876658</accession><cross_references><pubmed>35633486</pubmed><doi>10.1007/s40263-022-00921-5</doi></cross_references></HashMap>